Company news from the 01/16/07 news brief

Share this article:
Genizon BioSciences announced a license and collaboration agreement with Pfizer for diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis. Genizon retains therapeutic rights. Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with diseases. Pfizer will also purchase an equity stake in Genizon subject to certain closing conditions. Financial terms were not disclosed. Redi-Direct Marketing has acquired New York-based Dialog Group, including the firm’s Healthcare Dialog division, a developer of relationship marketing and communication programs for the pharmaceutical industry. Financial terms of the deal were not disclosed. CMPMedica has acquired MediReach Healthcare Communications, a Shanghai, China, consultancy providing medical and pharmaceutical marketing services to multinational pharmaceutical companies across China, for an initial payment of $1.1 million and as much as $2.75 million contingent on future performance.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.